Why is Glaxosmi. Pharma falling/rising?

As of 05-Aug, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,828.00, which reflects a decrease of 37.25 or 1.3%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 11.49% during this period. Despite this recent downturn, the company has shown strong performance year-to-date with a return of 25.87%. However, it has underperformed the sector by 0.35% today and is currently trading below its 5-day, 20-day, 50-day, and 100-day moving averages, although it remains above the 200-day moving average. The company benefits from high management efficiency, indicated by a return on equity (ROE) of 42.32%, and a low debt-to-equity ratio, which may provide some stability amid the recent price drop.
In the broader market context, Glaxosmithkline's short-term performance has been significantly worse than the benchmark, with a 1-week return of -9.77% compared to the Sensex's -0.77%. This stark contrast highlights the stock's recent struggles relative to the overall market. While the stock has seen rising investor participation, as evidenced by a 15.6% increase in delivery volume, the overall sentiment appears negative, contributing to its recent price decline. The company's majority shareholders being promoters may provide some confidence, but the current market dynamics and recent performance suggest a challenging environment for the stock.